{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T09:49:02Z","timestamp":1775209742107,"version":"3.50.1"},"reference-count":83,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009077","name":"Otsuka America Pharmaceutical, Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009077","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,23]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>IgA nephropathy often presents with chronic nephron loss and clinical chronic kidney disease. It is thus important that non IgA specific interventions are deployed to help sustain kidney function and structure. This review details interventions in lifestyle and medications that exist and are arising to best meet this important challenge.<\/jats:p>","DOI":"10.1093\/ndt\/gfaf225","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T12:37:05Z","timestamp":1761568625000},"page":"i27-i34","source":"Crossref","is-referenced-by-count":1,"title":["How should we best manage the consequences of nephron loss in IgAN?"],"prefix":"10.1093","volume":"41","author":[{"given":"Jackson","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Medicine (Nephrology), Stanford University Medical Center , Stanford, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fahmeedah","family":"Kamal","sequence":"additional","affiliation":[{"name":"Department of Medicine (Nephrology), Stanford University Medical Center , Stanford, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brittany","family":"Yeung","sequence":"additional","affiliation":[{"name":"Department of Medicine (Nephrology), Stanford University Medical Center , Stanford, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Lafayette","sequence":"additional","affiliation":[{"name":"Department of Medicine (Nephrology), Stanford University Medical Center , Stanford, CA ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"2026022304270285200_bib1","doi-asserted-by":"publisher","first-page":"e1002765","DOI":"10.1371\/journal.pgen.1002765","article-title":"Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis","volume":"8","author":"Kiryluk","year":"2012","journal-title":"PLoS Genet"},{"key":"2026022304270285200_bib2","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1159\/000509997","article-title":"A personalized update on IgA nephropathy: a new vision and new future challenges","volume":"144","author":"Guti\u00e9rrez","year":"2020","journal-title":"Nephron"},{"key":"2026022304270285200_bib3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","article-title":"Long-term outcomes in IgA nephropathy","volume":"18","author":"Pitcher","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026022304270285200_bib4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.36469\/001c.26129","article-title":"A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin A nephropathy","volume":"8","author":"Kwon","journal-title":"J Health Econ Outcomes Res"},{"key":"2026022304270285200_bib5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.semnephrol.2007.10.001","article-title":"Natural history of primary IgA nephropathy","volume":"28","author":"Berthoux","year":"2008","journal-title":"Semin Nephrol"},{"key":"2026022304270285200_bib6","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1093\/ndt\/gfx242","article-title":"Long-term outcome in 145 patients with assumed benign immunoglobulin A nephropathy","volume":"32","author":"Knoop","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2026022304270285200_bib7","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1053\/j.ajkd.2007.03.013","article-title":"A novel simpler histological classification for renal survival in IgA nephropathy: a retrospective study","volume":"49","author":"Manno","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"2026022304270285200_bib8","doi-asserted-by":"publisher","first-page":"e91756","DOI":"10.1371\/journal.pone.0091756","article-title":"Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan","volume":"9","author":"Moriyama","year":"2014","journal-title":"PLoS ONE"},{"key":"2026022304270285200_bib9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ekir.2017.08.008","article-title":"Life expectancy for patients from the southeastern United States with IgA nephropathy","volume":"3","author":"Hastings","year":"2018","journal-title":"Kidney Int Rep"},{"key":"2026022304270285200_bib10","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3390\/jcm13040947","article-title":"An update on current therapeutic options in IgA nephropathy","volume":"13","author":"Lim","year":"2024","journal-title":"J Clin Med"},{"key":"2026022304270285200_bib11","doi-asserted-by":"publisher","first-page":"CD003962","DOI":"10.1002\/14651858.CD003962.pub2","article-title":"Non-immunosuppressive treatment for IgA nephropathy","author":"Reid","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"2026022304270285200_bib12","doi-asserted-by":"publisher","first-page":"CD003962","DOI":"10.1002\/14651858.CD003962.pub3","article-title":"Non-immunosuppressive treatment for IgA nephropathy","volume":"2","author":"Tunnicliffe","year":"2024","journal-title":"Cochrane Database Syst Rev"},{"key":"2026022304270285200_bib13","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1681\/ASN.2006040347","article-title":"IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria","volume":"18","author":"Coppo","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2026022304270285200_bib14","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1097\/01.ASN.0000068460.37369.DC","article-title":"Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial","volume":"14","author":"Praga","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"2026022304270285200_bib15","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1053\/j.ajkd.2006.01.017","article-title":"Hong Kong study using Valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study","volume":"47","author":"Li","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"2026022304270285200_bib16","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"2026022304270285200_bib17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2215\/CJN.03350708","article-title":"Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D)","volume":"4","author":"Fried","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026022304270285200_bib18","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2026022304270285200_bib19","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026022304270285200_bib20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","article-title":"A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy","volume":"100","author":"Wheeler","year":"2021","journal-title":"Kidney Int"},{"key":"2026022304270285200_bib21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"2026022304270285200_bib22","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","article-title":"Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials","volume":"400","author":"Nuffield Department of Population Health Renal Studies Group, SGLT2 Inhibitor Meta-Analysis Cardio-Renal Trialists\u2019 Consortium","year":"2022","journal-title":"Lancet"},{"key":"2026022304270285200_bib23","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1056\/nejmoa2409183","article-title":"Long-term effects of Empagliflozin in patients with chronic kidney disease","volume":"392","author":"The EMPA-KIDNEY Collaborative Group","year":"2025","journal-title":"N Engl J Med"},{"key":"2026022304270285200_bib24","article-title":"Physiology, Endothelin","author":"Titus","year":"2023","journal-title":"StatPearls"},{"key":"2026022304270285200_bib25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.semnephrol.2015.02.004","article-title":"Endothelin and the renal vasculature","volume":"35","author":"Guan","year":"2015","journal-title":"Semin Nephrol"},{"key":"2026022304270285200_bib26","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1093\/ndt\/gfq534","article-title":"Endothelin type A and B receptors in the control of afferent and efferent arterioles in mice","volume":"26","author":"Schildroth","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"2026022304270285200_bib27","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1038\/sj.bjp.0706412","article-title":"ETA and ETB receptors differentially modulate afferent and efferent arteriolar responses to endothelin","volume":"146","author":"Inscho","year":"2005","journal-title":"Br J Pharmacol"},{"key":"2026022304270285200_bib28","doi-asserted-by":"publisher","first-page":"i69","DOI":"10.1093\/ndt\/gft339","article-title":"Endothelin antagonism for patients with chronic kidney disease: still a hope for the future","volume":"29 Suppl 1","author":"Schneider","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2026022304270285200_bib29","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1681\/ASN.2016060666","article-title":"Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment","volume":"28","author":"Tonneijck","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026022304270285200_bib30","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(09)61500-2","article-title":"A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial","volume":"374","author":"Weber","year":"2009","journal-title":"Lancet"},{"key":"2026022304270285200_bib31","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1681\/ASN.2012040355","article-title":"Endothelin-A receptor antagonism modifies cardiovascular risk factors in CKD","volume":"24","author":"Dhaun","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2026022304270285200_bib32","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2026022304270285200_bib33","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1016\/S0140-6736(19)30772-X","article-title":"Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial","volume":"393","author":"Heerspink","year":"2019","journal-title":"Lancet"},{"key":"2026022304270285200_bib34","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.kint.2023.08.014","article-title":"Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease","volume":"104","author":"Chan","year":"2023","journal-title":"Kidney Int"},{"key":"2026022304270285200_bib35","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/S0140-6736(23)02230-4","article-title":"Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial","volume":"402","author":"Heerspink","year":"2023","journal-title":"Lancet"},{"key":"2026022304270285200_bib36","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1056\/NEJMoa2409415","article-title":"Atrasentan in patients with IgA nephropathy","volume":"392","author":"Heerspink","year":"2025","journal-title":"N Engl J Med"},{"key":"2026022304270285200_bib37","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1056\/NEJMoa2308550","article-title":"Sparsentan versus Irbesartan in focal segmental glomerulosclerosis","volume":"389","author":"Rheault","year":"2023","journal-title":"N Engl J Med"},{"key":"2026022304270285200_bib38","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","article-title":"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial","volume":"402","author":"Rovin","year":"2023","journal-title":"Lancet"},{"key":"2026022304270285200_bib39","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1681\/asn.0000000538","article-title":"The selective endothelin receptor antagonist SC0062 in IgA nephropathy: a randomized double-blind placebo-controlled clinical trial","volume":"36","author":"Heerspink","year":"2025","journal-title":"J Am Soc Nephrol"},{"key":"2026022304270285200_bib40","doi-asserted-by":"publisher","first-page":"S178","DOI":"10.1016\/j.ekir.2024.02.364","article-title":"WCN24-1868 Assist: a randomized, double-blind, placebo-controlled crossover trial of atrasentan in patients with IgA nephropathy (IGAN) on Sglt2i","volume":"9","author":"Noronha","year":"2024","journal-title":"Kidney Int Rep"},{"key":"2026022304270285200_bib41","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf116.0313","article-title":"Sparsentan (SPAR) added to stable sodium-glucose cotransporter-2 inhibitors (SGLT2is) in adults with IgA nephropathy (IgAN) in the phase 2 SPARTACUS trial","volume":"40","author":"Ayoub","year":"2025","journal-title":"Nephrology Dialysis Transplantation"},{"key":"2026022304270285200_bib42","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae394","article-title":"First real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors","volume":"18","author":"Schanz","year":"2025","journal-title":"Clin Kidney J"},{"key":"2026022304270285200_bib43","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1210\/endo-125-4-2224","article-title":"Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors","volume":"125","author":"Funder","year":"1989","journal-title":"Endocrinology"},{"key":"2026022304270285200_bib44","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1126\/science.3037703","article-title":"Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor","volume":"237","author":"Arriza","year":"1987","journal-title":"Science"},{"key":"2026022304270285200_bib45","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/bs.vh.2018.09.004","article-title":"Mechanisms of mineralocorticoid receptor signaling","volume":"109","author":"Fuller","year":"2019","journal-title":"Vitam Horm"},{"key":"2026022304270285200_bib46","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41440-018-0158-6","article-title":"Pathophysiological mechanisms of mineralocorticoid receptor-dependent cardiovascular and chronic kidney disease","volume":"42","author":"Nishiyama","year":"2019","journal-title":"Hypertens Res"},{"key":"2026022304270285200_bib47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1254\/jphs.10r07cr","article-title":"Pathophysiological roles of aldosterone and mineralocorticoid receptor in the kidney","volume":"115","author":"Rafiq","year":"2011","journal-title":"J Pharmacol Sci"},{"key":"2026022304270285200_bib48","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.mce.2011.07.018","article-title":"Mineralocorticoid receptors in the pathophysiology of chronic kidney diseases and the metabolic syndrome","volume":"350","author":"Shibata","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"2026022304270285200_bib49","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1159\/000518254","article-title":"Direct blood pressure-independent anti-fibrotic effects by the selective nonsteroidal mineralocorticoid receptor antagonist finerenone in progressive models of kidney fibrosis","volume":"52","author":"Droebner","year":"2021","journal-title":"Am J Nephrol"},{"key":"2026022304270285200_bib50","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1161\/CIRCULATIONAHA.107.748640","article-title":"Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines","volume":"117","author":"Guo","year":"2008","journal-title":"Circulation"},{"key":"2026022304270285200_bib51","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1681\/ASN.2005111196","article-title":"Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats","volume":"17","author":"Han","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2026022304270285200_bib52","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1113\/JP277002","article-title":"RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition","volume":"597","author":"Koszegi","year":"2019","journal-title":"J Physiol"},{"key":"2026022304270285200_bib53","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000515622","article-title":"Aldosterone and mineralocorticoid receptor signaling as determinants of cardiovascular and renal injury: from Hans Selye to the present","volume":"52","author":"Epstein","year":"2021","journal-title":"Am J Nephrol"},{"key":"2026022304270285200_bib54","doi-asserted-by":"publisher","first-page":"T23","DOI":"10.1530\/JOE-17-0060","article-title":"30 Years of the mineralocorticoid receptor: coregulators as mediators of mineralocorticoid receptor signalling diversity","volume":"234","author":"Fuller","year":"2017","journal-title":"J Endocrinol"},{"key":"2026022304270285200_bib55","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/cphy.c130044","article-title":"The multifaceted mineralocorticoid receptor","volume":"4","author":"Gomez-Sanchez","year":"2014","journal-title":"Compr Physiol"},{"key":"2026022304270285200_bib56","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int"},{"key":"2026022304270285200_bib57","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"2026022304270285200_bib58","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2026022304270285200_bib59","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026022304270285200_bib60","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2026022304270285200_bib61","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/ndt\/gfae132","article-title":"Design and baseline characteristics of the finerenone, in addition to standard of care, on the progression of kidney disease in patients with non-diabetic chronic kidney disease (FIND-CKD) randomized trial","volume":"40","author":"Heerspink","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026022304270285200_bib62","doi-asserted-by":"publisher","first-page":"i59","DOI":"10.1093\/ndt\/gfae258","article-title":"Combination therapy as a new standard of care in diabetic and non-diabetic chronic kidney disease","volume":"40","author":"Neuen","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026022304270285200_bib63","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/s0140-6736(23)02408-x","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"key":"2026022304270285200_bib64","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"2026022304270285200_bib65","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2\u00b74\u00a0mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"key":"2026022304270285200_bib66","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"2026022304270285200_bib67","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"2026022304270285200_bib68","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"key":"2026022304270285200_bib69","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/oby.23673","article-title":"Two-year effect of semaglutide 2.4\u00a0mg on control of eating in adults with overweight\/obesity: STEP 5","volume":"31","author":"Wharton","year":"2023","journal-title":"Obesity"},{"key":"2026022304270285200_bib70","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"2026022304270285200_bib71","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1038\/s41591-024-03327-6","article-title":"Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial","volume":"31","author":"Apperloo","year":"2025","journal-title":"Nat Med"},{"key":"2026022304270285200_bib72","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","article-title":"Executive summary of the KDIGO 2024 Clinical Practice Guideline for the evaluation and management of chronic kidney disease: known knowns and known unknowns","volume":"105","author":"Levin","year":"2024","journal-title":"Kidney Int"},{"key":"2026022304270285200_bib73","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1053\/j.ajkd.2020.05.006","article-title":"KDOQI Clinical Practice Guideline for nutrition in CKD: 2020 update","volume":"76","author":"Ikizler","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2026022304270285200_bib74","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0272-6386(12)80313-1","article-title":"The modification of diet in renal disease study: design, methods, and results from the feasibility study","volume":"20","year":"1992","journal-title":"Am J Kidney Dis"},{"key":"2026022304270285200_bib75","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/S0272-6386(96)90099-2","article-title":"Effects of dietary protein restriction on the progression of advanced renal disease in the modification of diet in renal disease study","volume":"27","author":"Levey","year":"1996","journal-title":"Am J Kidney Dis"},{"key":"2026022304270285200_bib76","article-title":"Dietary protein restriction and the progression of chronic renal disease: what have all of the results of the MDRD study shown?","volume":"10","author":"Levey","journal-title":"J Am Soc Nephrol"},{"key":"2026022304270285200_bib77","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1053\/j.ajkd.2007.02.278","article-title":"Efficacy and safety of a very-low-protein diet when postponing dialysis in the elderly: a prospective randomized multicenter controlled study","volume":"49","author":"Brunori","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"2026022304270285200_bib78","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1053\/j.jrn.2019.07.005","article-title":"The effects of restricted protein diet supplemented with ketoanalogue on renal function, blood pressure, nutritional status, and chronic kidney disease-mineral and bone disorder in chronic kidney disease patients: a systematic review and meta-analysis","volume":"30","author":"Chewcharat","year":"2020","journal-title":"J Ren Nutr"},{"key":"2026022304270285200_bib79","doi-asserted-by":"publisher","first-page":"CD001892","DOI":"10.1002\/14651858.CD001892.pub3","article-title":"Low protein diets for chronic kidney disease in non diabetic adults","author":"Fouque","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"2026022304270285200_bib80","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s11255-015-1170-2","article-title":"Effect of restricted protein diet supplemented with keto analogues in chronic kidney disease: a systematic review and meta-analysis","volume":"48","author":"Jiang","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"2026022304270285200_bib81","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/jcsm.12264","article-title":"Low-protein diet for conservative management of chronic kidney disease: a systematic review and meta-analysis of controlled trials","volume":"9","author":"Rhee","year":"2018","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"2026022304270285200_bib82","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.34572","article-title":"Lifestyle modifications and nutritional and therapeutic interventions in delaying the progression of chronic kidney disease: a review","volume-title":"Cureus","author":"Alkhatib","year":"2023"},{"key":"2026022304270285200_bib83","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2147\/IJNRD.S430377","article-title":"Practical considerations for the use of Sparsentan in the treatment of patients with IgAN in clinical practice","volume":"16","author":"Campbell","year":"2023","journal-title":"Int J Nephrol Renov Dis"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfaf225\/65050010\/gfaf225.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/Supplement_1\/i27\/65050010\/gfaf225.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/Supplement_1\/i27\/65050010\/gfaf225.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T09:27:10Z","timestamp":1771838830000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/Supplement_1\/i27\/8307504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":83,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2025,10,31]]},"published-print":{"date-parts":[[2026,2,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaf225","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,10,31]]}}}